MarginsXMarginsX
Home › Markets › Health Care › SMMT

Summit Therapeutics Inc. Common Stock (SMMT)

SMMT trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$11.82
-16.47% on the day
Market cap
$9.5B
Mid cap
Revenue · 2024
$0
Prior year not contiguous
Net income · 2024
-$221.3M

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2024-12-31, https://www.sec.gov/Archives/edgar/data/1599298/000159929825000048/0001599298-25-000048-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2024-12-31.

Profile

FieldValue
TickerSMMT on Nasdaq
SectorHealth Care
IndustryBiotechnology: Pharmaceutical Preparations
CountryUnited States
IPO year2015
SEC CIK0001599298
SEC industry codePharmaceutical Preparations
Incorporated inDELAWARE

Financials · 2024

LineValue
Revenue$0
Net income-$221.3M
Operating income-$226.0M
Net marginNeeds revenue and net income
Operating marginOperating income not reported
Revenue growthNo prior-year revenue to compare
Cash$104.9M
Total assets$435.6M
P/E (computed)Net income was not positive
P/S (computed)Needs market cap and revenue

Warning signs

Cash runway
3.4 months
$150.8M cash at September 30, 2026
Share count, 1 year
+7.4%
2025-10-14 to 2026-10-30 · +14.1% over 3 years
Going-concern doubt
No
10-Q filed November 4, 2026
Insider net buying, 12 months
$62.7M
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-04
Cash and burn$150.8M cash; operating cash flow -$131.3M a quarter.Report 2026-09-30
Shares outstanding799,763,918 (2026-10-30); 744,442,538 a year earlier; 700,842,898 three years earlier.Cover page 2026-10-30
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months1 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the marketLatest 2026-07-23
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorPricewaterhouseCoopers LLP, San Jose, California, United StatesPCAOB Form AP 2026-03-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $62.7M, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
Not filed-$208.4M-$159.8M$150.8MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2026
2026-06-30
Not filed-$215.7M-$141.1M$419.4MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2026
2026-03-31
Not filed-$189.4M-$122.3M$106.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2025
2025-12-31
Not filed-$219.2M-$101.9M$225.3MNo debt tagsNeeds four quarters10-K 2026-02-23
Q3 2025
2025-09-30
Not filed-$231.8M-$93.1M$238.6MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q2 2025
2025-06-30
Not filed-$565.7M-$66.7M$297.9MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q1 2025
2025-03-31
Not filed-$62.9M-$61.2M$211.5MNo debt tagsNeeds four quarters10-Q 2026-11-04
Q4 2024
2024-12-31
$0-$61.2M-$48.7M$104.9MNo debt tags$010-K 2025-02-24

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering document424B72026-11-04
Latest annual report10-K2026-02-23
Latest quarterly / interim10-Q2026-11-04
Latest current report8-K2026-11-16
Latest proxyDEF 14A2026-10-19

Source: SEC EDGAR submissions feed, 565 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-13.3%
1 month-8.8%
3 months+1.1%
Year to date-19.1%
1 year-22.5%
From 52-week high-46.4%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: Pharmaceutical Preparations

TickerCompanyPriceDayMarket cap
SYRESpyre Therapeutics Inc.$99.37-4.45%$9.4B
TGTXTG Therapeutics Inc.$62.76-2.71%$9.5B
MDGLMadrigal Pharmaceuticals Inc.$423.96-0.80%$9.8B
PRAXPraxis Precision Medicines Inc.$310.27-5.44%$8.7B
PTGXProtagonist Therapeutics Inc.$124.83-4.67%$8.1B
BMRNBioMarin Pharmaceutical Inc.$57.99+1.33%$11.2B
ALKSAlkermes plc$46.53-1.06%$7.8B
CORTCorcept Therapeutics Incorporated$69.22-5.10%$7.6B

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier